MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.
Stocks · News reference
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Gold Tumbles Over 3%; MongoDB Shares Move Lower
U.S. stocks fell Monday, led by a 150-point Nasdaq drop. Energy rose, communication services slid; Knorex and Kodiak surged, while MongoDB tumbled.
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
Dow Dips Over 200 Points; Dallas Fed’s Manufacturing Index Declines In September
U.S. stocks fell Monday as the Dow dropped 200+ points; Nasdaq and S&P 500 also slid. Health care rose, while communication services lagged.
Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.